CYP2C9*2 and CYP2C9*3 allele variants of CYP2C9 cytochrome gene in St. Petersburg population, and their clinical role in warfarin anticoagulant therapy
Abstract
One of the leading anticoagulants in Russia is warfarin. Its pharmacokinetics is determined by structural polymorphisms of CYP2C9 cytochrome gene, metabolizing warfarin. In the present study, the authors analyzed: 1) prevalence of two allele variants of this gene; 2) patients' individual reaction to warfarin, according to their CYP2C9 genotype. It was demonstrated that: 1) prevalence of CYP2C9 gene allele variants in St. Petersburg population was 82,66% (CYP2C9*1), 11,11% (CYP2C9*2), and 6,32% (CYP2C9*3); 2) individuals with CYP2C9*2 and CYP2C9*3 alleles reached therapeutic hypocoagulation faster, and required significantly lower weekly doses of the medication. Routine identification of CYP2C9*2 and CYP2C9*3 alleles is recommended to all patients administered warfarin.
About the Authors
O. V. Sirotkina
Петербургский институт ядерной физики им. Б.П. Константинова РАН
Russian Federation
Russian Federation
A. S. Ulitina
Санкт-Петербургский государственный медицинский университет им. И.П. Павлова
Russian Federation
Russian Federation
A. E. Taraskina
Петербургский институт ядерной физики им. Б.П. Константинова РАН
Russian Federation
Russian Federation
M. I. Kadinskaya
Санкт-Петербургский государственный медицинский университет им. И.П. Павлова
Russian Federation
Russian Federation
T. V. Vavilova
Санкт-Петербургский государственный медицинский университет им. И.П. Павлова
Russian Federation
Russian Federation
S. N. Pchelina
Петербургский институт ядерной физики им. Б.П. Константинова РАН; Санкт-Петербургский государственный медицинский университет им. И.П. Павлова
Russian Federation
Russian Federation
E. I. Shwartz
Петербургский институт ядерной физики им. Б.П. Константинова РАН; Санкт-Петербургский государственный медицинский университет им. И.П. Павлова
Russian Federation
Russian Federation
References
1. Aithal G.P., Day С.Р., Kesteven P.J.L., Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications//Lancet. -1999.-V. 353. P. 717-719.
2. Higashi M.K., Veenstra D.L., Kondo L.M. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy//JAMA. -2002. -V. 287. P. 1690-1698.
3. Lee C.R., Goldstein J.A., Pieper J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data//Pharmacogenetics. -2002. -V. 12. P. 251-263.
4. Lim V., Pande I. Lefiunomide can potentiate the anticoagulant effect of warfarine.//BMJ. -2002. -V. 325. -P. 1333-1334.
5. Mannucci P.M. Genetic control of anticoagulation//Lancet. -1999.-V. 353.-P. 688-689.
6. Margaglione M., Colazzo D., D'Andrea G. et al. Genetic modulation of oral anticoagulation with warfarin//Thromb. Haemost. -2000.-V. 84.-P. 775-778.
7. Miners J.O., Birkett D.J. Cytochrome P450 2C9: an enzyme of major importance in human drug metabolism//Br. J. Clin. Pharmacol. -1998. -V. 45. -P. 525-536. 11.
8. Tabrizi A.R., Zehnbauer B.A., Borecki L.B. et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin//J. Am. Coll. Surg. -2002. -V. 194. -P. 267-273.
9. Tassies D., Freire C., Puoan J., Maragall S. Et al. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation//Haematologica. -2002. -V. 87. -P. 1185-1191.
10. Taube J., Halsell D., Baglin T. Influence of cytochrom P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of overanticoagulation in patients on long-term treatment//Blood. -2000. -V. 96. -P. 1816-1819.
11. Yasar U., Eliasson E., Dahl M.-L. et al. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population//Biochem. Biophys. Res. Commun. -1999. -V. 254. -P. 628-631.
12. Young-Ran Yoon, Ji-Hong Shon, Moon-Kyung Kim et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population//Br. J. Clin. Pharmacol. -2001. -V. 51. -P. 277-280.
Review
For citations:
Sirotkina O.V., Ulitina A.S., Taraskina A.E., Kadinskaya M.I., Vavilova T.V., Pchelina S.N., Shwartz E.I. CYP2C9*2 and CYP2C9*3 allele variants of CYP2C9 cytochrome gene in St. Petersburg population, and their clinical role in warfarin anticoagulant therapy. Russian Journal of Cardiology. 2004;(6):47-50. (In Russ.)
Views:
1004
Email this article 